196 related articles for article (PubMed ID: 34410522)
1. Suppressed PLIN3 frequently occurs in prostate cancer, promoting docetaxel resistance via intensified autophagy, an event reversed by chloroquine.
Lamprou I; Tsolou A; Kakouratos C; Mitrakas AG; Xanthopoulou ET; Kassela K; Karakasiliotis I; Zois CE; Giatromanolaki A; Koukourakis MI
Med Oncol; 2021 Aug; 38(10):116. PubMed ID: 34410522
[TBL] [Abstract][Full Text] [Related]
2. Lipophagy-Related Protein Perilipin-3 and Resistance of Prostate Cancer to Radiation Therapy.
Lamprou I; Kakouratos C; Tsolou A; Pavlidis P; Xanthopoulou ET; Nanos C; Tsaroucha A; Sivridis E; Giatromanolaki A; Koukourakis MI
Int J Radiat Oncol Biol Phys; 2022 Jun; 113(2):401-414. PubMed ID: 35121129
[TBL] [Abstract][Full Text] [Related]
3. ACSS3 represses prostate cancer progression through downregulating lipid droplet-associated protein PLIN3.
Zhou L; Song Z; Hu J; Liu L; Hou Y; Zhang X; Yang X; Chen K
Theranostics; 2021; 11(2):841-860. PubMed ID: 33391508
[TBL] [Abstract][Full Text] [Related]
4. Autophagic flux determines cell death and survival in response to Apo2L/TRAIL (dulanermin).
Singh K; Sharma A; Mir MC; Drazba JA; Heston WD; Magi-Galluzzi C; Hansel D; Rubin BP; Klein EA; Almasan A
Mol Cancer; 2014 Mar; 13():70. PubMed ID: 24655592
[TBL] [Abstract][Full Text] [Related]
5. FOXM1 contributes to docetaxel resistance in castration-resistant prostate cancer by inducing AMPK/mTOR-mediated autophagy.
Lin JZ; Wang WW; Hu TT; Zhu GY; Li LN; Zhang CY; Xu Z; Yu HB; Wu HF; Zhu JG
Cancer Lett; 2020 Jan; 469():481-489. PubMed ID: 31738958
[TBL] [Abstract][Full Text] [Related]
6. PrLZ increases prostate cancer docetaxel resistance by inhibiting LKB1/AMPK-mediated autophagy.
Zeng J; Liu W; Fan YZ; He DL; Li L
Theranostics; 2018; 8(1):109-123. PubMed ID: 29290796
[No Abstract] [Full Text] [Related]
7. Overexpression of SLC6A1 associates with drug resistance and poor prognosis in prostate cancer.
Chen C; Cai Z; Zhuo Y; Xi M; Lin Z; Jiang F; Liu Z; Wan Y; Zheng Y; Li J; Zhou X; Zhu J; Zhong W
BMC Cancer; 2020 Apr; 20(1):289. PubMed ID: 32252682
[TBL] [Abstract][Full Text] [Related]
8. CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity.
Qian DZ; Rademacher BL; Pittsenbarger J; Huang CY; Myrthue A; Higano CS; Garzotto M; Nelson PS; Beer TM
Prostate; 2010 Mar; 70(4):433-42. PubMed ID: 19866475
[TBL] [Abstract][Full Text] [Related]
9. Autophagy pathway is required for IL-6 induced neuroendocrine differentiation and chemoresistance of prostate cancer LNCaP cells.
Chang PC; Wang TY; Chang YT; Chu CY; Lee CL; Hsu HW; Zhou TA; Wu Z; Kim RH; Desai SJ; Liu S; Kung HJ
PLoS One; 2014; 9(2):e88556. PubMed ID: 24551118
[TBL] [Abstract][Full Text] [Related]
10. A Mammalian Target of Rapamycin-Perilipin 3 (mTORC1-Plin3) Pathway is essential to Activate Lipophagy and Protects Against Hepatosteatosis.
Garcia-Macia M; Santos-Ledo A; Leslie J; Paish HL; Collins AL; Scott RS; Watson A; Burgoyne RA; White S; French J; Hammond J; Borthwick LA; Mann J; Bolaños JP; Korolchuk VI; Oakley F; Mann DA
Hepatology; 2021 Dec; 74(6):3441-3459. PubMed ID: 34233024
[TBL] [Abstract][Full Text] [Related]
11. NPRL2 promotes docetaxel chemoresistance in castration resistant prostate cancer cells by regulating autophagy through the mTOR pathway.
Luo S; Shao L; Chen Z; Hu D; Jiang L; Tang W
Exp Cell Res; 2020 May; 390(2):111981. PubMed ID: 32234375
[TBL] [Abstract][Full Text] [Related]
12. MiR-129-5p promotes docetaxel resistance in prostate cancer by down-regulating CAMK2N1 expression.
Wu C; Miao C; Tang Q; Zhou X; Xi P; Chang P; Hua L; Ni H
J Cell Mol Med; 2020 Feb; 24(3):2098-2108. PubMed ID: 31876385
[TBL] [Abstract][Full Text] [Related]
13. The transcription factor ZEB1 promotes chemoresistance in prostate cancer cell lines.
Orellana-Serradell O; Herrera D; Castellón EA; Contreras HR
Asian J Androl; 2019; 21(5):460-467. PubMed ID: 30880686
[TBL] [Abstract][Full Text] [Related]
14. STEAP1 Knockdown Decreases the Sensitivity of Prostate Cancer Cells to Paclitaxel, Docetaxel and Cabazitaxel.
Rocha SM; Nascimento D; Coelho RS; Cardoso AM; Passarinha LA; Socorro S; Maia CJ
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047621
[TBL] [Abstract][Full Text] [Related]
15. Synergistic anti-tumor effects of Liraglutide, a glucagon-like peptide-1 receptor agonist, along with Docetaxel on LNCaP prostate cancer cell line.
Eftekhari S; Montazeri H; Tarighi P
Eur J Pharmacol; 2020 Jul; 878():173102. PubMed ID: 32283060
[TBL] [Abstract][Full Text] [Related]
16. NOTCH3 promotes docetaxel resistance of prostate cancer cells through regulating TUBB3 and MAPK signaling pathway.
Sun X; Zhang Y; Xin S; Jin L; Cao Q; Wang H; Wang K; Liu X; Tang C; Li W; Li Z; Wen X; Yang G; Guo C; Liu Z; Ye L
Cancer Sci; 2024 Feb; 115(2):412-426. PubMed ID: 38115797
[TBL] [Abstract][Full Text] [Related]
17. Tau oligomers accumulation sensitizes prostate cancer cells to docetaxel treatment.
Martellucci S; Clementi L; Sabetta S; Muzi P; Mattei V; Bologna M; Angelucci A
J Cancer Res Clin Oncol; 2021 Jul; 147(7):1957-1971. PubMed ID: 33811272
[TBL] [Abstract][Full Text] [Related]
18. Use of miR‑145 and testicular nuclear receptor 4 inhibition to reduce chemoresistance to docetaxel in prostate cancer.
Zhu J; Qin P; Cao C; Dai G; Xu L; Yang D
Oncol Rep; 2021 Mar; 45(3):963-974. PubMed ID: 33650661
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Janus Kinase 1 synergizes docetaxel sensitivity in prostate cancer cells.
Nalairndran G; Chung I; Abdul Razack AH; Chung FF; Hii LW; Lim WM; Looi CK; Mai CW; Leong CO
J Cell Mol Med; 2021 Sep; 25(17):8187-8200. PubMed ID: 34322995
[TBL] [Abstract][Full Text] [Related]
20. Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis.
Boutin B; Tajeddine N; Vandersmissen P; Zanou N; Van Schoor M; Mondin L; Courtoy PJ; Tombal B; Gailly P
Prostate; 2013 Jul; 73(10):1090-102. PubMed ID: 23532738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
